Filomena Giovanni Battista, Gentile Barbara Cristina, Albanesi Luca, Bellavia Fabrizio, D'Ascenzo Roberto, Vermiglio Mauro, Ghahhari Jamil, Riolo Sara, Lombardo Riccardo, Giulianelli Roberto
Department of Urology, Fondazione Policlinico Universitario Agostino Gemelli, "Università Cattolica del Sacro Cuore," Rome, Italy.
Ospedale Regina Apostolorum, Albano Laziale, Italy.
J Endourol. 2023 Jul;37(7):811-816. doi: 10.1089/end.2022.0685. Epub 2023 Jun 14.
The aim of our study is to assess the long-term outcomes and safety of bipolar transurethral plasma enucleation of the prostate (B-TUEP) in patients with lower urinary tract symptoms (LUTS) in a single-center cohort study. Our focus is to evaluate the impact on outcomes after 10 years of follow-up (FUP) in terms of recurrence, LUTS, and patients' quality of life after B-TUEP in prostates between 30 and 80 cc. Between May 2010 and December 2011, all consecutive patients with benign prostatic hyperplasia undergoing B-TUEP were prospectively enrolled in our study. Data on patients' history, physical examination, prostate volumes, erectile function, prostate-specific antigen levels, International Prostate Symptoms Score (IPSS), and uroflowmetry were collected at 0, 1, 3, 6, 12, 24, 36, 60, and 120 months. Early and long-term complications were recorded. A total of 50 consecutive patients underwent B-TUEP in our facility, all performed by a single surgeon (R.G.). Twelve patients were excluded during the 10 years. No patients had persistent bladder outlet obstruction (BOO) requiring reoperation. In terms of results, the improvement in IPSS was sustained throughout 5 years, and the mean difference from baseline at 5 years was 17 points, with similar results at 10 years. Erectile function was also slightly improved after surgery and maintained for the next 5 years, with a slight age-related decrease at 10 years. Furthermore, the improvements in maximum urine flow rate (Qmax) were maintained at 5 years, with a mean improvement of 16 mL/s, while at 10 years, it settled on a mean improvement from baseline of 12 mL/s. In our 10 years' experience, B-TUEP is a safe and highly effective technique for relieving BOO, with excellent outcomes and no recurrence at 10 years of FUP. Further multicenter studies should confirm our results.
在一项单中心队列研究中,我们的研究目的是评估双极经尿道前列腺等离子剜除术(B-TUEP)对下尿路症状(LUTS)患者的长期疗效和安全性。我们的重点是评估在30至80立方厘米前列腺中进行B-TUEP术后10年随访(FUP)对复发、LUTS和患者生活质量的影响。2010年5月至2011年12月,所有连续接受B-TUEP治疗的良性前列腺增生患者均被前瞻性纳入我们的研究。在0、1、3、6、12、24、36、60和120个月时收集患者病史、体格检查、前列腺体积、勃起功能、前列腺特异性抗原水平、国际前列腺症状评分(IPSS)和尿流率的数据。记录早期和长期并发症。我们机构共有50例连续患者接受了B-TUEP治疗,均由同一外科医生(R.G.)完成。10年间有12例患者被排除。没有患者因持续性膀胱出口梗阻(BOO)需要再次手术。就结果而言,IPSS的改善在5年内持续存在,5年时与基线的平均差值为17分,10年时结果相似。术后勃起功能也略有改善,并在接下来的5年中维持,10年时与年龄相关略有下降。此外,最大尿流率(Qmax)的改善在5年时得以维持,平均改善16毫升/秒,而在10年时,从基线的平均改善稳定在12毫升/秒。根据我们10年的经验,B-TUEP是一种安全且高效的缓解BOO的技术,疗效极佳,在10年随访时无复发。进一步的多中心研究应证实我们的结果。